Editas Medicine, Inc. EDIT

$OBSV Analysts expect $16-$36 per share.

Shareholders will be ecstatic, with their stake up 30% over the past week following ObsEva SA‘s (NASDAQ:OBSV) latest quarterly results. Revenues came in 113% better than analyst models expected, at US$4.0kwhile statutory losses per share were US$0.48, in line with forecasts. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year

There are two markets Dow and Nasdaq. The leaders of Tech are back in a bull market. 5G is alive and kicking. There is money to be made in any market. My advice to anyone is to stay invested with 20-30 percent in cash.

Exactly......their going to clear you to keep poking someone in the eye with no results. Just a matter of time before this explodes without warning

Agreed agreed agreed

CC was basically a summation of the press release verbatim. They seemed optimistic regarding LCA 10 and Sickle Cell going forward. No questions came from audience.

Listened

Interesting option trading too 516 contracts on the May 45

Nope. Think the cats out the bag. Tomorrow will be very interesting to say the least. Blessings to all

100 is just the first stop 200 is in 3mo over the next 12mo 400 plus isn’t off the table.

I agree if they were not making progress with LCA10 they would not announce moving on to tumors. Any day folks any day.